The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma

REFERENCES

• Sabel M. S., Sondak V. K. Pros and cons of adjuvant interferon in the treatment of melanoma. Oncologist 2003; 8: 451–458
   PubMed Web of Science ®Google Scholar
• Kirkwood J. M., Tarhini A. A. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova) 2003; 13: 127–140, quiz 187–128
   PubMedGoogle Scholar
• Agarwala S. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. Am. J. Clin. Dermatol. 2003; 4(5)333–346
   PubMed Web of Science ®Google Scholar
• Anichini A., Vegetti C., Mortarini R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother. 2004; 53(10)855–864
   PubMed Web of Science ®Google Scholar
• Monsurro V., Wang E., Panelli M. C., et al. Active-specific immunization against melanoma: is the problem at the receiving end?. Semin. Cancer Biol. 2003; 13(6)473–480
   PubMed Web of Science ®Google Scholar
• Khong H. T., Restifo N. P. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol. 2002; 3(11)999–1005
   PubMed Web of Science ®Google Scholar
• Yamshchikov G. V., Mullins D. W., Chang C. C., et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 2005; 174(11)6863–6871
   PubMed Web of Science ®Google Scholar
• Holmberg D., Cilio C. M., Lundholm M., Motta V. CTLA-4 (CD152) and its involvement in autoimmune disease. Autoimmunity. 2005; 38(3)225–233
   PubMed Web of Science ®Google Scholar
• Chambers C. A., Kuhns M. S., Egen J. G., Allison J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 2001; 19: 565–594
   PubMed Web of Science ®Google Scholar
• Wang X. B., Giscombe R., Yan Z., Heiden T., Xu D., Lefvert A K. Expression of CTLA-4 by human monocytes. Scand. J. Immunol. 2002; 55(1)53–60
   PubMed Web of Science ®Google Scholar
• Blomhoff A., Kemp E. H., Gawkrodger D. J., et al. CTLA4 polymorphisms are associated with vitiligo, in patients with concomitant autoimmune diseases. Pigment Cell Res. 2005; 18(1)55–58
   PubMedGoogle Scholar
• Blomhoff A., Lie B. A., Myhre A. G., et al. Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease. J. Clin. Endocrinol. Metab. 2004; 89(7)3474–3476
   PubMed Web of Science ®Google Scholar
• Sharpe A. H., Freeman G. J. The B7-CD28 superfamily. Nat. Rev. Immunol. 2002; 2(2)116–126
   PubMed Web of Science ®Google Scholar
• Lindsten T., Lee K. P., Harris E. S., et al. Characterization of CTLA-4 structure and expression on human T cells. J. Immunol. 1993; 151(7)3489–3499
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Lenschow D. J., Bakker C. Y., et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1(5)405–413
   PubMed Web of Science ®Google Scholar
• Walunas T. L., Bakker C. Y., Bluestone J. A. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 1996; 183(6)2541–2550
   PubMed Web of Science ®Google Scholar
• Finn P. W., He H., Wang Y., et al. Synergistic induction of CTLA-4 expression by costimulation with TCR plus CD28 signals mediated by increased transcription and messenger ribonucleic acid stability. J. Immunol. 1997; 158(9)4074–4081
   PubMed Web of Science ®Google Scholar
• Jago C. B., Yates J., Camara N. O., Lechler R. I., Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin. Exp. Immunol. 2004; 136(3)463–471
   PubMed Web of Science ®Google Scholar
• Chattopadhyay S., Chakraborty N. G., Mukherji B. Regulatory T cells and tumor immunity. Cancer Immunol. Immunother. 2005; 54(12)1153–1161
   PubMed Web of Science ®Google Scholar
• Birebent B., Lorho R., Lechartier H., et al. Suppressive properties of human CD4+CD25+ regulatory T cells are dependent on CTLA-4 expression. Eur. J. Immunol. 2004; 34(12)3485–3496
   PubMed Web of Science ®Google Scholar
• Kataoka H., Takahashi S., Takase K., et al. CD25(+)CD4(+) regulatory T cells exert in vitro suppressive activity independent of CTLA-4. Int. Immunol. 2005; 17(4)421–427
   PubMed Web of Science ®Google Scholar
• Tang Q., Boden E. K., Henriksen K. J., Bour-Jordan H., Bi M., Bluestone J. A. Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Eur. J. Immunol. 2004; 34(11)2996–3005
   PubMed Web of Science ®Google Scholar
• Hara T., Fu S. M., Hansen J. A. Human T cell activation. II. A new activation pathway used by a major T cell population via a disulfide-bonded dimer of a 44 kilodalton polypeptide (9.3 antigen). J. Exp. Med. 1985; 161(6)1513–1524
   PubMed Web of Science ®Google Scholar
• Collins A. V., Brodie D. W., Gilbert R. J., et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17(2)201–210
   PubMed Web of Science ®Google Scholar
• Sansom D. M. CD28, CTLA-4 and their ligands: who does what and to whom?. Immunology 2000; 101(2)169–177
   PubMed Web of Science ®Google Scholar
• Manzotti C. N., Tipping H., Perry L. C., et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur. J. Immunol. 2002; 32(10)2888–2896
   PubMed Web of Science ®Google Scholar
• Krummel M. F., Allison J. P. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995; 182(2)459–465
   PubMed Web of Science ®Google Scholar
• Thompson C. B., Lindsten T., Ledbetter J. A., et al. CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA. 1989; 86(4)1333–1337
   PubMed Web of Science ®Google Scholar
• Lucas P. J., Negishi I., Nakayama K., Fields L. E., Loh D. Y. Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response. J. Immunol. 1995; 154(11)5757–5768
   PubMed Web of Science ®Google Scholar
• Boise L. H., Minn A. J., Noel P. J., et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 1995; 3(1)87–98
   PubMed Web of Science ®Google Scholar
• Sperling A. I., Auger J. A., Ehst B. D., Rulifson I. C., Thompson C. B., Bluestone J. A. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 1996; 157(9)3909–3917
   PubMed Web of Science ®Google Scholar
• Wu L. X., La Rose J., Chen L., et al. CD28 regulates the translation of Bcl-xL via the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway. J. Immunol. 2005; 174(1)180–194
   PubMed Web of Science ®Google Scholar
• Krummel M. F., Allison J. P. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J. Exp. Med. 1996; 183(6)2533–2540
   PubMed Web of Science ®Google Scholar
• Brunner M. C., Chambers C. A., Chan F. K., Hanke J., Winoto A., Allison J. P. CTLA-4-Mediated inhibition of early events of T cell proliferation. J. Immunol. 1999; 162(10)5813–5820
   PubMed Web of Science ®Google Scholar
• Kubsch S., Graulich E., Knop J., Steinbrink K. Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1. Eur. J. Immunol. 2003; 33(7)1988–1997
   PubMed Web of Science ®Google Scholar
• Greenwald R. J., Oosterwegel M. A., van der Woude D., et al. CTLA-4 regulates cell cycle progression during a primary immune response. Eur. J. Immunol. 2002; 32(2)366–373
   PubMed Web of Science ®Google Scholar
• Vanasek T. L., Khoruts A., Zell T., Mueller D. L. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 2001; 167(10)5636–5644
   PubMed Web of Science ®Google Scholar
• Greenwald R. J., Boussiotis V. A., Lorsbach R. B., Abbas A. K., Sharpe A. H. CTLA-4 regulates induction of anergy in vivo. Immunity. 2001; 14(2)145–155
   PubMed Web of Science ®Google Scholar
• Morgensztern D., McLeod H. L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005; 16(8)797–803
   PubMed Web of Science ®Google Scholar
• Contardi E., Palmisano G. L., Tazzari P L., et al. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer. 2005; 117(4)538–550
   PubMed Web of Science ®Google Scholar
• Tivol E. A., Borriello F., Schweitzer A. N., Lynch W. P., Bluestone J. A., Sharpe A. H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995; 3(5)541–547
   PubMed Web of Science ®Google Scholar
• Waterhouse P., Penninger J. M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270(5238)985–988
   PubMed Web of Science ®Google Scholar
• Mandelbrot D. A., McAdam A. J., Sharpe A. H. B7-1 or B7-2 is required to produce the lymphoproliferative phenotype in mice lacking cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). J. Exp. Med. 1999; 189(2)435–440
   PubMed Web of Science ®Google Scholar
• Tirapu I., Huarte E., Guiducci C., et al. Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res. 2006; 66(4)2442–2450
   PubMed Web of Science ®Google Scholar
• Leach D. R., Krummel M. F., Allison J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996; 271(5256)1734–1736
   PubMed Web of Science ®Google Scholar
• Kwon E. D., Hurwitz A. A., Foster B. A., et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA. 1997; 94(15)8099–8103
   PubMed Web of Science ®Google Scholar
• Kwon E. D., Foster B. A., Hurwitz A. A., et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA 1999; 96(26)15074–15079
   PubMed Web of Science ®Google Scholar
• Yang Y. F., Zou J. P., Mu J., et al. Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: the effect is manifested only at the restricted tumor-bearing stages. Cancer Res. 1997; 57(18)4036–4041
   PubMed Web of Science ®Google Scholar
• Shrikant P., Khoruts A., Mescher M. F. CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity. 1999; 11(4)483–493
   PubMed Web of Science ®Google Scholar
• LaBelle J. L., Hanke C. A., Blazar B. R., Truitt R. L. Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia. Blood. 2002; 99(6)2146–2153
   PubMed Web of Science ®Google Scholar
• Hurwitz A. A., Yu T. F., Leach D. R., Allison J. P. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA. 1998; 95(17)10067–10071
   PubMed Web of Science ®Google Scholar
• Perrin P. J., Maldonado J. H., Davis T. A., June C. H., Racke M. K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 1996; 157(4)1333–1336
   PubMed Web of Science ®Google Scholar
• Karandikar N. J., Vanderlugt C. L., Walunas T. L., Miller S. D., Bluestone J. A. CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 1996; 184(2)783–788
   PubMed Web of Science ®Google Scholar
• Vijayakrishnan L., Slavik J. M., Illes Z., et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 2004; 20(5)563–575
   PubMed Web of Science ®Google Scholar
• Prud'homme G. J., Chang Y., Li X. Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Hum. Gene Ther. 2002; 13(3)395–406
   PubMed Web of Science ®Google Scholar
• Bergman M. L., Cilio C. M., Penha-Goncalves C., et al. CTLA-4−/− mice display T cell-apoptosis resistance resembling that ascribed to autoimmune-prone non-obese diabetic (NOD) mice. J. Autoimmun. 2001; 16(2)105–113
   PubMed Web of Science ®Google Scholar
• Quattrocchi E., Dallman M. J., Feldmann M. Adenovirus-mediated gene transfer of CTLA-4Ig fusion protein in the suppression of experimental autoimmune arthritis. Arthritis Rheum. 2000; 43(8)1688–1697
   PubMed Web of Science ®Google Scholar
• Nierkens S., Aalbers M., Bol M., et al. Differential requirement for CD28/CTLA-4-CD80/CD86 interactions in drug-induced type 1 and type 2 immune responses to trinitrophenyl-ovalbumin. J. Immunol. 2005; 175(6)3707–3714
   PubMed Web of Science ®Google Scholar
• Cunnane G., Chan O. T., Cassafer G., et al. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide. Arthritis Rheum. 2004; 50(5)1539–1548
   PubMed Web of Science ®Google Scholar
• Walker L. S., Ausubel L. J., Chodos A., Bekarian N., Abbas A. K. CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. J. Immunol. 2002; 169(11)6202–6209
   PubMed Web of Science ®Google Scholar
• Bass K. K., Mastrangelo M. J. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol. Immunother. 1998; 47(1)1–12
   PubMed Web of Science ®Google Scholar
• Berd D., Sato T., Cohn H., Maguire H. C., Jr., Mastrangelo M. J. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int. J. Cancer. 2001; 94(4)531–539
   PubMed Web of Science ®Google Scholar
• Kleinknecht S., Bichler K. H., Strohmaier W. L. Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma. Urol. Int. 1992; 48(1)1–8
   PubMed Web of Science ®Google Scholar
• Gorelik L., Prokhorova A., Mokyr M. B. Low-dose melphalan-induced shift in the production of a Th2-type cytokine to a Th1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother. 1994; 39(2)117–126
   PubMed Web of Science ®Google Scholar
• Mokyr M. B., Kalinichenko T., Gorelik L., Bluestone J. A. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 1998; 58(23)5301–5304
   PubMed Web of Science ®Google Scholar
• Faries M. B., Hsueh E. C., Shu S., Famatiga E., Morton D. L. Post-vaccination CTLA-4 expression correlates inversely with survival in patients vaccinated with allogeneic melanoma cell vaccine. J. Clin. Oncol. 2004; 22(14S), abstr. #2565
   Google Scholar
• van Elsas A., Hurwitz A. A., Allison J. P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 1999; 190(3)355–366
   PubMed Web of Science ®Google Scholar
• Ji Q., Gondek D., Hurwitz A. A. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J. Immunol. 2005; 175(3)1456–1463
   PubMed Web of Science ®Google Scholar
• van Elsas A., Sutmuller R. P., Hurwitz A. A., et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 2001; 194(4)481–489
   PubMed Web of Science ®Google Scholar
• Sutmuller R. P., van Duivenvoorde L. M., van Elsas A., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 2001; 194(6)823–832
   PubMed Web of Science ®Google Scholar
• Gregor P. D., Wolchok J. D., Ferrone C. R., et al. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. Vaccine. 2004; 22(13–14))1700–1708
   PubMed Web of Science ®Google Scholar
• White R. R., Sullenger B. A., Rusconi C. P. Developing aptamers into therapeutics. J. Clin. Invest. 2000; 106(8)929–934
   PubMed Web of Science ®Google Scholar
• Keler T., Halk E., Vitale L., et al. Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques. J. Immunol. 2003; 171(11)6251–6259
   PubMed Web of Science ®Google Scholar
• Hanson D. C., Canniff P. C., Primiano M. J., et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Proc. Amer. Assoc. Cancer Res. 2004; 45, abstr 3802
   Google Scholar
• Canniff P. C., Donovan C. B., Burkwit J. J., et al. CP-675,206 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease. Proc. Amer. Assoc. Cancer Res. 2004; 45, abstr 709
   Google Scholar
• Ribas A., Bozon V. A., Lopez-Berestein G., et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. J. Clin. Oncol. 2005; 23(16S)716s, abstr. 7524
   Google Scholar
• Tchekmedyian S., Glasby J., Korman A., Keler T., Deo Y., Davis T. MDX-010 (human anti-CTLA4): a phase I trial in malignant melanoma. Proc. Am. Soc. Clin. Oncol. 2002; 21, (abstr 56)
   Google Scholar
• Davis T. A., Tchekmedyian S., Korman A., et al. MDX-010 (human anti-CTLA4): a phase 1 trial in hormone refractory prostate carcinoma (HRPC). Proc. Am. Soc. Clin. Oncol. 2002; 21, abstr 74
   Google Scholar
• Sanderson K., Scotland R., Lee P., et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 2005; 23(4)741–750
   PubMed Web of Science ®Google Scholar
• Weber J. S., Targan S., Scotland R., et al. Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. J. Clin. Oncol. 2006; 24(18s), 102s abstr 2510
   Google Scholar
• Phan G. Q., Haworth L. R., Duray P. H., Davis T. A., Rosenberg S. A. Blockade of CTLA-4 with MDX-010 in humans can induce both autoimmunity and cancer regression. Proc. Am. Soc. Clin. Oncol. 2003; 22, abstr. 3424
   Google Scholar
• Phan G. Q., Yang J. C., Sherry R. M., et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 2003; 100(14)8372–8377
   PubMed Web of Science ®Google Scholar
• Attia P., Phan G. Q., Maker A. V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005; 23(25)6043–6053
   PubMed Web of Science ®Google Scholar
• Phan G. Q., Touloukian C. E., Yang J. C., et al. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J. Immunother. 2003; 26(4)349–356
   PubMed Web of Science ®Google Scholar
• Maker A. V., Attia P., Rosenberg S. A. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 2005; 175(11)7746–7754
   PubMed Web of Science ®Google Scholar
• Maker A. V., Phan G. Q., Attia P., et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann. Surg. Oncol. 2005; 12(12)1005–1016
   PubMed Web of Science ®Google Scholar
• Wang X. B., Zheng C. Y., Giscombe R., Lefvert A. K. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand. J. Immunol. 2001; 54(5)453–458
   PubMed Web of Science ®Google Scholar
• Hersh E. M., Weber J., Powderly J., et al. A phase II, randomized multi-center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. J. Clin. Oncol. 2004; 22(14S), abstr. 7511
   Google Scholar
• Fischkoff S. A., Hersh E. M., Weber J., et al. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. J. Clin. Oncol. 2005; 23(16S)716S, abstr. 7525
   Google Scholar
• Beck K. E., Blansfield J. A., Tran K. Q., et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J. Clin. Oncol. 2006; 24(15)2283–2289
   PubMed Web of Science ®Google Scholar
• Camacho L. H., Ribas A., Glaspy J. A., et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies. J. Clin. Oncol. 2004; 22(14S), abstr. 2505
   Google Scholar
• Ribas A., Camacho L. H., Lopez-Berestein G., et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 2005; 23(35)8968–8977
   PubMed Web of Science ®Google Scholar
• Bulanhagui C. A., Ribas A., Pavlov D., et al. Phase I clinical trials of ticilimumab: Tumor responses are sufficient but not necessary for prolonged survival. J. Clin. Oncol. 2006; 24(18s)461s, abstr. 8036
   Google Scholar
• Reuben J. M., Lee B. N., Shen D. Y., et al. Therapy with human monoclonal anti-CTLA-4 antibody, CP-675,206, reduces regulatory T cells and IL-10 production in patients with advanced malignant melanoma (MM). J. Clin. Oncol. 2005; 23(16s)711s, abstr. 7505
   Google Scholar
• Reuben J. M., Lee B. N., Li C., et al. Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer. 2006; 106(11)2437–2444
   PubMed Web of Science ®Google Scholar
• Gomez-Navarro J., Sharma A., Bozon V. A., et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma. J. Clin. Oncol. 2006; 24(18s)460s, abstr. 8032
   PubMedGoogle Scholar
• Ribas A., Comin-Anduix B., Bozon V. A., et al. Antigen-specific T cell responses in patients with melanoma treated with the CTLA4 blocking mAb ticilimumab. J. Clin. Oncol. 2006; 24(18s)461s, abstr. 8033
   Google Scholar
• Fong L., Kavanagh B., Rini B. I., Shaw V., Weinberg V., Small E. J. A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer. J. Clin. Oncol. 2006; 24(18s), abstr. 2508
   Google Scholar
• Gulley J. L., Theoret M. R., Dahut W., Pazdur W., Schlom J., Arlen M. Phase I trial of an enhanced PSA-based vaccine and anti-CTLA-4 antibody in patients (pts) with metastatic androgen independent prostate cancer (AIPC). Proc. Am. Soc. Clin. Oncol. 2006, 2006 Prostate Cancer Symposium), abstr. 355
   PubMed Web of Science ®Google Scholar
• Gerritsen W., Van Den Eertwegh A. J., De Gruijl T., et al. A dose-escalation trial of GM-CSF-gene transduced allogeneic prostate cancer cellular immunotherapy in combination with a fully human anti-CTLA antibody (MDX-010, ipilimumab) in patients with metastatic hormone-refractory prostate cancer (mHRPC). Proc. Am. Soc. Clin. Oncol. 2006; 24(18s), abstr 2500
   Google Scholar
• Small E., Higano C., Tchekmedyian N., et al. Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. Proc. Am. Soc. Clin. Oncol. 2006; 24(18s), abstr 4609
   Google Scholar
• Yang J. C., Beck K. E., Blansfield J. A., Tran K. Q., Lowy I., Rosenberg S. A. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). J. Clin. Oncol. 2005; 23(16s), abstr. 2501
   Google Scholar
• Hodi F. S., Seiden M., Butler M., et al. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). J. Clin. Oncol. 2004; 22(14s), abstr. 2536
   Google Scholar
• Bashey A., Loza O., Medina B., et al. BEAM Versus CEB Conditioning for Autologous Transplantation in Patients with Non-Hodgkin's Lymphoma and Hodgkin's Disease: A Single Center Comparative Study of 219 Patients. Blood 2005; 106, (ASH Annual Meeting Abstracts), abstr 2079
   Google Scholar
• Zhong R. K., Loken M., Lane T. A., Ball E. D. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy. 2006; 8(1)3–12
   PubMed Web of Science ®Google Scholar
• Comin-Anduix B., Gualberto A., Glaspy J. A., et al. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin. Cancer. Res. 2006; 12(1)107–116
   PubMed Web of Science ®Google Scholar
• Hamid O., Urba W. J., Yellin M., et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J. Clin. Oncol. 2007; 25(18s)478s, abstr. 8525
   Google Scholar
• Ribas A., Antonia S., Sosman J., et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J. Clin. Oncol. 2007; 25(18s)118s, abstr. 3000
   PubMedGoogle Scholar
• Gomez-Navarro J., Antonia S., Sosman J., et al. Survival of patients (pts) with metastatic melanoma treated with an anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study. J. Clin. Oncol. 2007; 25(18s)478s, abstr. 8524
   Google Scholar
• Antonia J., Sosman J., Kirkwood J. M., et al. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675, 206. J. Clin. Oncol. 2007; 25(18s)127s, abstr. 3038
   Google Scholar
• Straatsma B. R., Nusinowitz S., Young T. A., et al. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Amer. J. Ophthalmol. 2007; 143(6)958–969
   PubMed Web of Science ®Google Scholar
• Sharma A., Bumerts P., Gomez-Navarro J., et al. Clearance of monoclonal antibody (mAb) CP-675,206 by therapeutic plasma exchange (TPE) or plasmapheresis. J. Clin. Oncol. 2007; 25(18s)611s, abstr. 13515
   PubMedGoogle Scholar
• Blansfield J. A., Beck K. E., Tran K., et al. Cytotoxic T-lymphocyte-associated antigen-4 blockade can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 2005; 28(6)593–598
   PubMed Web of Science ®Google Scholar
• Jaber S. H., Cowen E. W., Haworth L. R., et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch. Dermatol. 2006; 142(2)166–172
   PubMed Web of Science ®Google Scholar